2 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Active not recruiting 1, Not yet recruiting 1 |
Follow 4-hydroxy-N-desmethyltamoxifen: new trials by email Literature Review of 4-hydroxy-N-desmethyltamoxifen trials Research Report on 4-hydroxy-N-desmethyltamoxifen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty (Z)-endoxifen - Precocious Puberty, Gonadotropin-dependent | Phase 2 | Not yet recruiting | Atossa Therapeutics, Inc. | 6 | 2027-03-01 | 2026-10-09 |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment Tamoxifen, Exemestane, Letrozole - Ductal Carcinoma in Situ | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 400 | 2024-02-17 | 2026-10-26 |
| (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (Z)-endoxifen, goserelin - Breast Neoplasms, Invasive Breast Cancer | Phase 2 | Active not recruiting | Atossa Therapeutics, Inc. | 87 | 2023-02-14 | 2026-07-08 |
| Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density Z-Endoxifen, Placebo - Breast Density | Phase 2 | Completed | Atossa Therapeutics, Inc. | 240 | 2021-12-21 | 2026-05-20 |
| Topical Endoxifen in Women Topical endoxifen, Placebo - Mammographic Breast Density | Phase 2 | Completed | Atossa Therapeutics, Inc. | 90 | 2018-04-09 | 2021-07-12 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
Breast Neoplasms (2) · Carcinoma, Intraductal, Noninfiltrating (1) · Hemangiosarcoma (1) · Neoplasms (1) · Pathologic Complete Response (1) · Puberty, Precocious (1) · Triple Negative Breast Neoplasms (1)
Atossa Therapeutics, Inc. (4) · QuantumLeap Healthcare Collaborative (2)
United States (4) · Sweden (2)
Laura Esserman, MD, MBA (2) · Per Hall, MD (2) · Alison Boyce, MD (1) · Matthew P Goetz, MD (1) · Steven Quay, MD (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35604960, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42070780, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224